gene

SNCA

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about SNCA: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

2843Connections

16Hypotheses

15Analyses

50Outgoing

50Incoming

5Experiments

18Debates

Summary

SNCA is a gene implicated in neurodegeneration research. Key relationships include: interacts with, associated with, activates. Associated with AD, ALI, ALS. Connected to 983 entities in the SciDEX knowledge graph.

View on Wiki →

AI-generated illustration · click image to enlarge

Regenerate portrait ↻

🧬 Gene Info

Gene Symbol	SNCA
Full Name	Alpha-Synuclein
Chromosome	4q22.1
Protein Type	Structural Protein
Target Class	Structural Protein
Function	Immunotherapy targeting alpha-synuclein aggregates or small molecules preventing aggregation
Mechanism of Action	Immunotherapy targeting alpha-synuclein aggregates or small molecules preventing aggregation
Primary Expression	Substantia nigra, Cerebral cortex, Presynaptic terminals
Druggability	Medium (0.49)
Clinical Stage	Phase II
Pathways	Akt, Alpha-Synuclein, Autophagy, Cell Cycle, Epigenetic
UniProt ID	P37840
NCBI Gene ID	6622
Ensembl ID	ENSG00000145335
OMIM	163890
GeneCards	SNCA
Human Protein Atlas	SNCA
Associated Diseases	AD, Aging, ALI, Alpha-Synucleinopathies, Als
Known Drugs/Compounds	ACI-7104.056, AFFITOPE PD01A, ASO, Cinpanemab, D-520, levodopa
Interactions	ABCA7, ABCD3, ACETYL-COA, ACLY, aco2, ACO2
SciDEX Target	View Target Profile (8 clinical trials)
SciDEX Hypotheses	SNCA conformer propagation across PD, DLB, and MSA Exosomal SNCA Propagation from Lysosome-Compromise SNCA Aggregation Hijacks the Endosomal Sorting Com (+7 more)
KG Connections	2840 knowledge graph edges
Databases	GeneCards HPA STRING

🧬 3D Structure Comparison — SNCA Experimental (PDB) vs Predicted (AlphaFold) — click to expand

📄 Experimental Structure

1XQ8 — X-ray / Cryo-EM

🔮 AI Predicted Structure

P37840 — AlphaFold

Left: Experimental structure from RCSB PDB | Right: AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (12)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    SNCA["SNCA"] -->|"modulates"| calcium["calcium"]
    SNCA["SNCA"] -->|"associated"| neurodegeneration["neurodegeneration"]
    SNCA["SNCA"] -->|"interacts"| DRD2["DRD2"]
    SNCA["SNCA"] -->|"interacts"| HSPA1A["HSPA1A"]
    SNCA["SNCA"] -->|"interacts"| DNMT1["DNMT1"]
    SNCA["SNCA"] -->|"encodes"| alpha_synuclein["alpha_synuclein"]
    DRD2_1["DRD2"] -->|"interacts"| SNCA["SNCA"]
    HSPA1A_2["HSPA1A"] -->|"interacts"| SNCA["SNCA"]
    DNMT1_3["DNMT1"] -->|"interacts"| SNCA["SNCA"]
    TLR4["TLR4"] -->|"interacts"| SNCA["SNCA"]
    style SNCA fill:#4a1a6b,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0

Outgoing (1438)

Target	Relation	Type	Str
SNCA	encodes	protein	0.00
Dementia	associated_with	disease	1.00
ALPHA_SYNUCLEIN	encodes	protein	1.00
alpha_synuclein	encodes	protein	1.00
dementia with Lewy bodies	associated_with	disease	1.00
Lewy bodies	part_of	pathway	1.00
alpha-synuclein	expresses	protein	1.00
Α-SYNUCLEIN	encodes	protein	0.99
Lewy body pathology	associated_with	phenotype	0.98
Lewy Bodies	biomarker_for	biomarker	0.98
PARKINSON'S DISEASE	associated_with	disease	0.95
MIRO1	upregulates	protein	0.95
Synucleinopathies	causes	disease	0.95
CD4 T Cell Activation	activates	process	0.95
Parkinson's Disease	component_of	disease	0.95
Lewy bodies	causes	phenotype	0.95
Parkinson Disease	associated_with	disease	0.95
Parkinson's Disease	associated_with	disease	0.95
Multiple System Atrophy	associated_with	disease	0.95
Inflammatory Response	associated_with	process	0.95
Parkinson's Disease with Dementia	associated_with	disease	0.95
alpha-synuclein	produces	protein	0.95
Dementia with Lewy Bodies	implicated_in	disease	0.95
MTOR	activates	protein	0.95
Als	associated_with	disease	0.95
Lewy Bodies	associated_with	biomarker	0.95
Parkinson Disease	biomarker_for	disease	0.95
Parkinson	associated_with	disease	0.95
Synucleinopathies	associated_with	disease	0.95
Alpha-Synucleinopathies	causes	disease	0.95
Neuronal α-synuclein Disease	risk_factor_for	disease	0.95
Parkinson's Disease	causes	disease	0.95
Lewy Body Formation	involved_in	process	0.95
Parkinson'S Disease	causes	disease	0.95
Microglial Autophagy	associated_with	process	0.95
Parkinson'S Disease With Dementia	involved_in	disease	0.95
Parkinson'S Disease	associated_with	disease	0.95
Parkinson'S Disease	biomarker_for	disease	0.95
alpha-synuclein aggregation	involved_in	process	0.95
Dementia With Lewy Bodies	associated_with	disease	0.95
ALPHA-SYNUCLEIN	encodes	protein	0.95
Amyloid Formation	involved_in	process	0.95
Microglia	interacts_with	cell_type	0.94
LAG3	interacts_with	protein	0.93
Neuroinflammation	associated_with	process	0.92
Lewy Body Aggregates	involved_in	mechanism	0.92
Mitochondria	interacts_with	cell_type	0.91
PARP1	activates	gene	0.90
Substantia Nigra Pars Compacta	associated_with	brain_region	0.90
Synucleinopathies	biomarker_for	disease	0.90

Incoming (1405)

Source	Relation	Type	Str
SNCA	encodes	gene	0.00
AMYLOID	associated_with	gene	1.00
PARKINSON'S DISEASE	associated_with	gene	1.00
TAU	associated_with	gene	1.00
NEURODEGENERATION	associated_with	gene	1.00
MICROGLIA	associated_with	gene	1.00
ALZHEIMER'S DISEASE	associated_with	gene	1.00
LAG3	binds	gene	0.95
ATC161	degrades	drug	0.95
Microglia	degrades	cell_type	0.95
AUTOTAC	targets	mechanism	0.95
Microglia	cleaves	cell_type	0.95
D-520	targets	drug	0.95
Rmab38E2-Scfv8D3	targets	drug	0.95
Rna G-Quadruplex	promotes	compound	0.95
Short-Chain Fatty Acids	modulates	compound	0.95
Autophagy-Lysosomal Pathway	interacts_with	pathway	0.92
Lu Af82422	targets	drug	0.90
h-072b2f5d	targets	hypothesis	0.90
Microglial Autophagy Disruption	causes	process	0.90
Cinpanemab	targets	drug	0.90
ACI-7104.056	targets	drug	0.90
Lactococcus Lactis Mg1363-Pmg36E-Glp-1	associated_with	drug	0.90
UB-312	targets	drug	0.90
Prasinezumab	targets	drug	0.90
h-b7ab85b6	targets	hypothesis	0.90
h-74777459	targets	hypothesis	0.90
PD03A	targets	drug	0.90
h-2e7eb2ea	targets	hypothesis	0.90
MEDI1341	targets	drug	0.90
AFFITOPE PD01A	targets	drug	0.90
SDA-2026-04-01-gap-20260401-225155	targets	analysis	0.90
ANTISENSE OLIGONUCLEOTIDES	downregulates	drug	0.90
PAP	associated_with	gene	0.90
SncaEnh+37	regulates	structure	0.90
NEURON	associated_with	cell_type	0.90
Chaperone-Mediated Autophagy	mediates	pathway	0.90
Antisense Oligonucleotide Therapy	downregulates	drug	0.90
Impaired Degradation	causes	mechanism	0.90
brain-derived extracellular vesicles	mediates	compound	0.90
Synucleinopathies	associated_with	disease	0.90
Autophagy	degrades	process	0.90
PBT434	inhibits	compound	0.90
Csga	associated_with	protein	0.90
Motor Deficits	associated_with	phenotype	0.88
ASO	inhibits	drug	0.87
LAMP2A	involved_in	protein	0.85
Macroautophagy	degrades	process	0.85
GBA1	regulates	gene	0.85
Phosphorylation	modulates	mechanism	0.85

Targeting Hypotheses (16)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
SNCA conformer propagation across PD, DLB, and MSA	0.820	multi	Cross-disease neurodegeneration mechanis
LAMP2A Liquid-Liquid Phase Separation Defects in Dopaminergi	0.783	neurodegeneration	-
PINK1/Parkin–TREM2 Axis: Convergent Mitophagy Failure Unifie	0.780	neurodegeneration	-
Exosomal SNCA Propagation from Lysosome-Compromised Neurons	0.777	neurodegeneration	-
SNCA Oligomer Binding to LAMP2A Cytosolic Tail Prevents Tors	0.733	neurodegeneration	-

NRF2-Mediated Proteostatic Convergence: Shared Oxidative Str	0.700	neurodegeneration	-
VPS35 Retromer Dysfunction Creates a GCase Trafficking Bottl	0.700	neurodegeneration	-
SNCA Aggregation Hijacks the Endosomal Sorting Complex Requi	0.690	neurodegeneration	-
m6A Hypermethylation of SNCA mRNA Stabilises Alpha-Synuclein	0.662	Parkinson disease	m6A RNA Modification and Alpha-Synuclein
Alpha-synuclein phosphorylation-dominated LLPS hijacks synap	0.657	Parkinson's disease	-
Physiological SCFAs may reduce alpha-synuclein burden primar	0.650	neurodegeneration	Do physiological concentrations of SCFAs
SNCA Oligomers Sequester TFEB Phosphatases to Create a Phosp	0.650	neurodegeneration	-
early PD proteogenomic hubs that are both causal enough and	0.626	neurodegeneration	Proteogenomic Network Hubs as Druggable
Neuronal Subtype-Specific Alpha-Synuclein Expression Normali	0.571	neurodegeneration	De Novo Binder Design Targeting Alpha-Sy
Sulfated glycans and metal-binding CSF proteins brace alpha-	0.489	neurodegeneration	Which specific CSF molecular components
H2S/butyrate imbalance drives enteric alpha-synuclein pathol	0.380	Parkinson's disease	-

Mentioning Analyses (15)

Scientific analyses that reference this entity

Cross-disease neurodegeneration mechanism synthesis

neurodegeneration | 2026-04-28 | 17 hypotheses Top: 0.828

Proteogenomic Network Hubs as Druggable Targets in Early PD Neurodegeneration

neurodegeneration | 2026-04-27 | 3 hypotheses Top: 0.626

Gut Microbiome Analysis in Parkinson's Disease

neurodegeneration | 2026-04-16 | 1 hypotheses Top: 0.778

De Novo Binder Design Targeting Alpha-Synuclein Aggregation Interface

neurodegeneration | 2026-04-16 | 1 hypotheses Top: 0.571

How does engineered C. butyricum cross the blood-brain barrier to directly bind

neurodegeneration | 2026-04-15 | 2 hypotheses Top: 0.699

Experiments (5)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Model	Status	Est. Cost
Long-term perampanel treatment in A53T BAC-SNCA mice with PFF injectio	validation	Lewy body disease	0.950	A53T BAC-SNCA transgenic mice	proposed	N/A
PFF uptake in primary hippocampal neurons with inhibitors	exploratory	Lewy body disease	0.900	mouse primary hippocampal neur	proposed	N/A
Dexamethasone treatment study in α-synuclein mice	validation	Parkinson's disease	0.850	Thy1.2-α-synuclein transgenic	proposed	N/A
PFF clearance kinetics in Snca knockout mice	validation	Lewy body disease	0.800	Snca knockout mice	proposed	N/A
Individuals with SNCA pathogenic variants reported painful dystonia, l	genetic_association	Parkinson's disease	0.500	human	extracted	N/A

Related Papers (3)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year
Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple sys [PMID:9682846]	Unknown	Neuroscience letters	1998
Mutation in the alpha-synuclein gene identified in families with Parkinson's dis [PMID:9197268]	Unknown	Science (New York, N.Y.)	1997
Alpha-synuclein in Lewy bodies. [PMID:9278044]	Unknown	Nature	1997

Debates (18)

Multi-agent debates referencing this entity

Which AD, PD, ALS, and FTD mechanisms recur across disease boundaries and yield

active · Rounds: 4 · Score: 0.72 · 2026-04-28

Which proteogenomic network hubs identified by multi-omics PD studies are drugga

active · Rounds: 4 · Score: 0.67 · 2026-04-28

This analysis aims to elucidate the mechanisms by which gut microbiome dysbiosis

closed · Rounds: 4 · Score: 0.82 · 2026-04-22

Can computational de novo protein binder design produce stable binders that bloc

closed · Rounds: 4 · Score: 0.70 · 2026-04-21

How does the gut microbiome composition differ between PD patients and healthy c

closed · Rounds: 4 · Score: 0.70 · 2026-04-21

Is the gut microbiome a driver of PD pathology via SCFA depletion, or is dysbios

closed · Rounds: 4 · Score: 0.70 · 2026-04-16

Can computationally designed binders against alpha-synuclein realistically trans

closed · Rounds: 4 · Score: 0.70 · 2026-04-16

The abstract claims C. butyricum-GLP-1 crosses the BBB and binds to GLP-1 recept

closed · Rounds: 4 · Score: 0.95 · 2026-04-15

PSP and CBD both involve 4R-tau but produce distinct neuropathological patterns

closed · Rounds: 4 · Score: 0.69 · 2026-04-12

Do bacterial curli amyloids cross the blood-brain barrier to directly seed α-syn

closed · Rounds: 4 · Score: 0.84 · 2026-04-12

Related Research

Hypotheses and analyses mentioning SNCA in their description or question text

SNCA

Understanding Entity Pages

Summary

Wiki Pages (12)

SNCA — Alpha-Synuclein

SNCA→Alpha-synuclein→Aggregation→Lewy Bodies→Synucleinopathies Causal Chain

SNCA A53T

SNCA-A53T Alpha-Synuclein Neurons

SNCA→Alpha-synuclein→Parkinson's Disease Causal Chain

CRISPRi Epigenetic Silencing of SNCA for Parkinson's Disease

SNCAG — Synuclein Gamma

SNCAIP Gene

SNCA — Alpha-Synuclein Gene Entity Page

SNCA Gene Variants and Mutations

SNCAIP Protein

SNCA-Overexpressing Dopaminergic Neurons

Pathway Diagram

Outgoing (1438)

Incoming (1405)

Targeting Hypotheses (16)

Mentioning Analyses (15)

Cross-disease neurodegeneration mechanism synthesis

Proteogenomic Network Hubs as Druggable Targets in Early PD Neurodegeneration

Gut Microbiome Analysis in Parkinson's Disease

De Novo Binder Design Targeting Alpha-Synuclein Aggregation Interface

How does engineered C. butyricum cross the blood-brain barrier to directly bind

Do bacterial curli amyloids cross the blood-brain barrier to directly seed α-syn

Does reduced Prevotellaceae abundance cause PD pathology or result from it?

What determines the specificity of DDR protein recruitment to dilncRNA-induced c

Which cell types show the most significant expression changes for neurodegenerat

SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas

Digital biomarkers and AI-driven early detection of neurodegeneration

4R-tau strain-specific spreading patterns in PSP vs CBD

What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's

Digital biomarkers and AI-driven early detection of neurodegeneration

What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's

Experiments (5)

Related Papers (3)

Debates (18)

Which AD, PD, ALS, and FTD mechanisms recur across disease boundaries and yield

Which proteogenomic network hubs identified by multi-omics PD studies are drugga

This analysis aims to elucidate the mechanisms by which gut microbiome dysbiosis

Can computational de novo protein binder design produce stable binders that bloc

How does the gut microbiome composition differ between PD patients and healthy c

Is the gut microbiome a driver of PD pathology via SCFA depletion, or is dysbios

Can computationally designed binders against alpha-synuclein realistically trans

The abstract claims C. butyricum-GLP-1 crosses the BBB and binds to GLP-1 recept

PSP and CBD both involve 4R-tau but produce distinct neuropathological patterns

Do bacterial curli amyloids cross the blood-brain barrier to directly seed α-syn

Related Research

m6A Hypermethylation of SNCA mRNA Stabilises Alpha-Synuclein Transcript and Prom

Physiological SCFAs may reduce alpha-synuclein burden primarily through a gut-fi

early PD proteogenomic hubs that are both causal enough and accessible enough to

Neuronal Subtype-Specific Alpha-Synuclein Expression Normalization

Sulfated glycans and metal-binding CSF proteins brace alpha-synuclein fibril pol